Jose A Garcia-Marco

Dr. Jose A Garcia-Marco

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2020 in Blood
Verified
Journal Article
Open access
PDF file
AMAnthony Mato
Anthony Mato
LRLindsey Roeker
Lindsey Roeker
NLNicole Lamanna
Nicole Lamanna
JAJohn Allan
John Allan
LLLori Leslie
Lori Leslie
TEToby Eyre
Toby Eyre
Given advanced age, comorbidities, and immune dysfunction, chronic lymphocytic leukemia (CLL) patients may be at particularly high risk of infection and poor outcomes related to coronavirus disease 2019 (COVID-19). Robust analysis of outcomes for CLL patients, particularly examining effects of baseline characteristics and CLL-directed therapy, is critical to optimally manage CLL patients through this evolving pandemic. CLL patients diagnosed with symptomatic COVID-19 across 43 international centers (n = 198) were included. Hospital admission occurred in 90%. Median age at COVID-19 diagnosis was 70.5 years. Median Cumulative Illness Rating Scale score was 8 (range, 4-32). Thirty-nine percent were treatment naive (“watch and wait”), while 61% had received ≥1 CLL-directed therapy (median, 2; range, 1-8). Ninety patients (45%) were receiving active CLL therapy at COVID-19 diagnosis, most commonly Bruton tyrosine kinase inhibitors (BTKi’s; n = 68/90 [76%]). At a median follow-up of 16 days, the overall case fatality rate was 33%, though 25% remain admitted. Watch-and-wait and treated cohorts had similar rates of admission (89% vs 90%), intensive care unit admission (35% vs 36%), intubation (33% vs 25%), and mortality (37% vs 32%). CLL-directed treatment with BTKi’s at COVID-19 diagnosis did not impact survival (case fatality rate, 34% vs 35%), though the BTKi was held during the COVID-19 course for most patients. These data suggest that the subgroup of CLL patients admitted with COVID-19, regardless of disease phase or treatment status, are at high risk of death. Future epidemiologic studies are needed to assess severe acute respiratory syndrome coronavirus 2 infection risk, these data should be validated independently, and randomized studies of BTKi’s in COVID-19 are needed to provide definitive evidence of benefit.

9 July 2020 in Leukemia
Verified
Journal Article
Closed access
PDF file
LSLydia Scarfò
Lydia Scarfò
TCThomas Chatzikonstantinou
Thomas Chatzikonstantinou
GRGian Matteo Rigolin
Gian Matteo Rigolin
GQGiulia Quaresmini
Giulia Quaresmini
MMMarina Motta
Marina Motta
PGPaolo Prospero Ghia
Paolo Prospero Ghia

1 November 2021 in Leukemia
Verified
Journal Article
Open access
PDF file
TCThomas Chatzikonstantinou
Thomas Chatzikonstantinou
AKAnargyros Kapetanakis
Anargyros Kapetanakis
LSLydia Scarfò
Lydia Scarfò
GKGeorgios Karakatsoulis
Georgios Karakatsoulis
David AllsupDavid Allsup
David Allsup
PGPaolo Prospero Ghia
Paolo Prospero Ghia
Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41–0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02–1.04; HR = 1.79, 95% CI:1.04–3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.

4 November 2021 in Blood
Verified
Journal Article
Open access
PDF file
LRLindsey Roeker
Lindsey Roeker
TEToby Eyre
Toby Eyre
MTMeghan C. Thompson
Meghan C. Thompson
NLNicole Lamanna
Nicole Lamanna
ACAlexander R. Coltoff
Alexander R. Coltoff
AMAnthony Mato
Anthony Mato
Lindsey Elizabeth Roeker, Toby Andrew Eyre, Meghan C. Thompson, Nicole Lamanna, Alexander Coltoff, Matthew S. Davids, Peter Baker, Lori A. Leslie, Kerry A. Roge

20 April 2009 in Cancer
Verified
Journal Article
Open access
PDF file
JGJose A Garcia-Marco
Jose A Garcia-Marco
CPCarlos Panizo
Carlos Panizo
EGEva Sanchez Garcia
Eva Sanchez Garcia
GDGuillermo Deben
Guillermo Deben
AAAlberto Alvarez‐Larran
Alberto Alvarez‐Larran
JGJose A. García‐Vela
Jose A. García‐Vela
BACKGROUND: Standard intrathecal chemotherapy for lymphomatous meningitis (LM) is limited by the short cerebrospinal half‐lives of the agents used, necessitating frequent administration. Liposomal cytarabine (DepoCyte) has an extended half‐life that permits administration at 2‐ to 4‐weekly intervals. METHODS: Patients with LM who underwent treatment with liposomal cytarabine at treatment centers in Spain between 2004 and 2007 were identified. Data on demographics, treatment, and outcomes were extracted from medical notes and entered, retrospectively, into a database for analysis. RESULTS: Data on 55 patients with lymphoma (mainly stage IV) and LM were entered into the database. Most patients (n = 36) had diffuse large B‐cell lymphoma. The median number of cycles of liposomal cytarabine received was 4 (range, 1‐10), and the median follow‐up period was 124 days. Complete and partial neurologic responses were achieved in 27 and 12 patients, respectively (overall response rate, 72%), all of whom also showed a cytological response, except for 5 with initially negative cytology. Median time to neurologic progression among responders was 105.5 days. Liposomal cytarabine was generally well tolerated; headache was the most commonly reported adverse effect (n = 17). CONCLUSIONS: Liposomal cytarabine is effective and well tolerated in the treatment of LM, and should be considered as an agent of choice for the treatment of this complication. Cancer 2009. © 2009 American Cancer Society.

10 August 2023 in Cancers
Verified
Journal Article
Open access
PDF file
JLJAVIER LOSCERTALES
JAVIER LOSCERTALES
PAPau Abrisqueta
Pau Abrisqueta
AGAntonio Gutierrez
Antonio Gutierrez
JHJosé-Ángel Hernández-Rivas
José-Ángel Hernández-Rivas
RARafael Andreu-Lapiedra
Rafael Andreu-Lapiedra
JGJose A Garcia-Marco
Jose A Garcia-Marco
The SRealCLL study aimed to obtain real-world evidence on the clinical characteristics and treatment patterns of patients with chronic lymphocytic leukemia (CLL) using natural language processing (NLP). Electronic health records (EHRs) from seven Spanish hospitals (January 2016–December 2018) were analyzed using EHRead® technology, based on NLP and machine learning. A total of 534 CLL patients were assessed. No treatment was detected in 270 (50.6%) patients (watch-and-wait, W&W). First-line (1L) treatment was identified in 230 (43.1%) patients and relapsed/refractory (2L) treatment was identified in 58 (10.9%). The median age ranged from 71 to 75 years, with a uniform male predominance (54.8–63.8%). The main comorbidities included hypertension (W&W: 35.6%; 1L: 38.3%; 2L: 39.7%), diabetes mellitus (W&W: 24.4%; 1L: 24.3%; 2L: 31%), cardiac arrhythmia (W&W: 16.7%; 1L: 17.8%; 2L: 17.2%), heart failure (W&W 16.3%, 1L 17.4%, 2L 17.2%), and dyslipidemia (W&W: 13.7%; 1L: 18.7%; 2L: 19.0%). The most common antineoplastic treatment was ibrutinib in 1L (64.8%) and 2L (62.1%), followed by bendamustine + rituximab (12.6%), obinutuzumab + chlorambucil (5.2%), rituximab + chlorambucil (4.8%), and idelalisib + rituximab (3.9%) in 1L and venetoclax (15.5%), idelalisib + rituximab (6.9%), bendamustine + rituximab (3.5%), and venetoclax + rituximab (3.5%) in 2L. This study expands the information available on patients with CLL in Spain, describing the diversity in patient characteristics and therapeutic approaches in clinical practice.